Physician profile
Peter Silberstein
NPI 1952415317
$98,732.06
in general payments reported to CMS, 2019-2025
43 companies · $9,643 in 2025
The $9,643 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $13K · 2021: $16K · 2022: $13K · 2023: $3,475 · 2024: $1,938 · 2025: $9,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,432 · Consulting Fee: $4,700 · Travel and Lodging: $867 · Food and Beverage: $686 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,432.00 |
| Consulting Fee | $4,700.00 |
| Travel and Lodging | $866.98 |
| Food and Beverage | $685.75 |
| Education | $371.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $52,732.13 | 2019-2023 | Pomalyst |
| Jazz Pharmaceuticals INC. | $9,686.48 | 2019-2025 | |
| Kite Pharma, INC. | $7,384.28 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $6,755.24 | 2019-2023 | Opdivo, Opdualag |
| Dova Pharmaceuticals | $6,629.85 | 2019-2020 | |
| Exelixis INC. | $5,430.81 | 2019-2021 | |
| Abbvie INC. | $2,991.50 | 2019-2024 | Venclexta |
| Karyopharm Therapeutics INC. | $2,250.00 | 2021 | |
| G1 Therapeutics, INC. | $1,514.06 | 2021-2022 | |
| Seagen INC. | $540.82 | 2019-2023 | |
| Genentech USA, INC. | $438.60 | 2019-2020 | |
| Lilly USA, LLC | $229.24 | 2019-2022 | |
| Janssen Biotech, INC. | $222.23 | 2019-2023 | Darzalex |
| Pfizer INC. | $160.42 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $153.86 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Silberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.